Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, today announced that the Company will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019, at 9:30 a.m. ET at the Marriott Copley Place in Boston. Maria Palasis, Ph.D., Lyras President and Chief Executive Officer, will provide an overview of the Company and a business update.
About Lyra Therapeutics Lyra Therapeutics is a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat (ENT) diseases, offering an alternative to conventional treatments or surgeries. The companys lead drug candidate, LYR-210, offers a novel approach for directing anti-inflammatory medicine deep into sinonasal tissues for up to six months of therapy. With proprietary expertise in drug development and materials science, Lyra is applying its transmucosal therapeutic system “ comprised of drug administered through a polymeric matrix “ with the goal of enabling therapeutic action at the site of inflammation in the sinonasal passages. Lyra Therapeutics is located in Watertown, Massachusetts. For more information, please visit www.lyratx.com.
The Yates Network